Seronegative CA LEMS in Small Cell Lung Cancer: Next Steps and the Role of Electrodiagnostic Testing

Dr. Primdahl addresses management of seronegative CA LEMS in a patient with SCLC and a compelling clinical picture. Options include repeating VGCC antibody testing (false-negatives occur for various pre-analytical reasons), broadening the panel with SOX1 and a paraneoplastic reflex screen, and, if the electrophysiologic picture is consistent with Lambert-Eaton, proceeding with treatment based on the clinical and electrophysiologic diagnosis without waiting for serologic confirmation. An empiric trial of amifampridine (Firdapse), the FDA-approved symptomatic treatment for CA LEMS, is another option: if symptoms improve with this potassium channel blocker, that response supports the clinical diagnosis. Dr. Primdahl explains the mechanism: blocking presynaptic potassium channels prolongs the action potential, enhances calcium influx, and thereby increases acetylcholine release at the neuromuscular junction, directly targeting the pathophysiology of LEMS.

Dr. Sen reinforces that the test that most reliably confirms CA LEMS when serology is uninformative is the electrodiagnostic nerve conduction study, specifically the single-fiber electromyography (EMG). This test directly measures neuromuscular junction communication and can confirm the diagnosis even when blood testing cannot. Critically, standard nerve conduction studies and EMG do not automatically include the post-exercise facilitation and high-frequency repetitive stimulation components required to detect LEMS. The referral order must explicitly state "evaluation for presynaptic neuromuscular junction dysfunction or LEMS" to ensure the appropriate protocol is used. VGCC antibody testing, broader serologic panels, and single-fiber EMG can all be ordered in parallel. There is no reason to wait for any one result before pursuing the others.